Chapter 3
Butyrylcholinesterase: Overview, Structure, and Function
Oksana Lockridge,
Ellen G. Duysen,
Patrick Masson,
Oksana Lockridge
University of Nebraska Medical Center, Eppley Institute, Omaha, NE, USA
Search for more papers by this authorEllen G. Duysen
University of Nebraska Medical Center, Eppley Institute, Omaha, NE, USA
Search for more papers by this authorPatrick Masson
University of Nebraska Medical Center, Eppley Institute, Omaha, NE, USA
Search for more papers by this authorOksana Lockridge,
Ellen G. Duysen,
Patrick Masson,
Oksana Lockridge
University of Nebraska Medical Center, Eppley Institute, Omaha, NE, USA
Search for more papers by this authorEllen G. Duysen
University of Nebraska Medical Center, Eppley Institute, Omaha, NE, USA
Search for more papers by this authorPatrick Masson
University of Nebraska Medical Center, Eppley Institute, Omaha, NE, USA
Search for more papers by this authorBook Editor(s):Tetsuo Satoh,
Ramesh C. Gupta,
Tetsuo Satoh
Department of Pharmacology and Toxicology, Japan
Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan
HAB Research Institute, Ichikawa, Chiba, Japan
Search for more papers by this authorRamesh C. Gupta
Toxicology Department, Breathitt Veterinary Center, Murray State University, Hopkinsville, KY, USA
Search for more papers by this authorSummary
This chapter contains sections titled:
-
Introduction
-
Name
-
History
-
Why was Butyrylcholinesterase Rather than Acetylcholinesterase Chosen as a Therapeutic?
-
Function of Butyrylcholinesterase Deduced from Studies In People
-
Function of Butyrylcholinesterase Deduced from the Knockout Mouse
-
Function of Butyrylcholinesterase Deduced from the G117H Transgenic Mouse
-
Function of Butyrylcholinesterase Deduced from the AChE Knockout Mouse
-
Function of Butyrylcholinesterase Deduced from Tissue-Specific Deletions of Acetylcholinesterase and Anchor Proteins
-
Function of Butyrylcholinesterase Deduced from Protection Experiments with Purified Butyrylcholinesterase
-
Butyrylcholinesterase in Human Tissues
-
Summary: Functions of Butyrylcholinesterase
-
Structure of Human Butyrylcholinesterase
-
Conclusions and Future Directions
-
Acknowledgments
-
References
REFERENCES
- Adler M, Manley HA, Purcell AL, Deshpande SS, Hamilton TA, Kan RK, Oyler G, Lockridge O, Duysen EG and Sheridan RE (2004). Reduced acetylcholine receptor density, morphological remodeling, and butyrylcholinesterase activity can sustain muscle function in acetylcholinesterase knockout mice. Muscle Nerve 30: 317–327.
- Allderdice PW, Gardner HA, Galutira D, Lockridge O, LaDu BN and McAlpine PJ (1991). The cloned butyrylcholinesterase (BCHE) gene maps to a single chromosome site, 3q26. Genomics 11: 452–454.
- Allon N, Raveh L, Gilat E, Cohen E, Grunwald J and Ashani Y (1998). Prophylaxis against soman inhalation toxicity in guinea pigs by pretreatment alone with human serum butyrylcholinesterase. Toxicol Sci 43: 121–128.
- Altamirano CV and Lockridge O (1999). Conserved aromatic residues of the C-terminus of human butyrylcholinesterase mediate the association of tetramers. Biochemistry 38: 13414–13422.
- Ashani Y (2000). Prospective of human butyrylcholinesterase as a detoxifying antidote and potential regulator of controlled-release drugs. Drug Develop Res 50: 298–308.
- Ashani Y, Shapira S, Levy D, Wolfe AD, Doctor BP and Raveh L (1991). Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice. Biochem Pharmacol 41: 37–41.
- Ashani Y, Peggins JO, III and Doctor BP (1992). Mechanism of inhibition of cholinesterases by huperzine A. Biochem Biophys Res Commun 184: 719–726.
- Balasubramanian AS and Bhanumathy CD (1993). Noncholinergic functions of cholinesterases. Faseb J 7: 1354–1358.
- Benzer A, Luz G, Oswald E, Schmoigl C and Menardi G (1992). Succinylcholine-induced prolonged apnea in a 3-week-old newborn: treatment with human plasma cholinesterase. Anesth Analg 74: 137–138.
- Bernard V, Brana C, Liste I, Lockridge O and Bloch B (2003). Dramatic depletion of cell surface m2 muscarinic receptor due to limited delivery from intracytoplasmic stores in neurons of acetylcholinesterase-deficient mice. Mol Cell Neurosci 23: 121–133.
- Blong RM, Bedows E and Lockridge O (1997). Tetramerization domain of human butyrylcholinesterase is at the C-terminus. Biochem J 327 (Pt 3): 747–757.
- Borders RW, Stephen CR, Nowill WK and Martin R (1955). The interrelationship of succinylcholine and the blood cholinesterases during anesthesia. Anesthesiology 16: 401–422.
- Boudinot E, Taysse L, Daulon S, Chatonnet A, Champagnat J and Foutz AS (2005). Effects of acetylcholinesterase and butyrylcholinesterase inhibition on breathing in mice adapted or not to reduced acetylcholinesterase. Pharmacol Biochem Behav 80: 53–61.
- Boudinot E, Bernard V, Camp S, Taylor P, Champagnat J, Krejci E and Foutz AS (2009). Influence of differential expression of acetylcholinesterase in brain and muscle on respiration. Respir Physiol Neurobiol 165: 40–48.
- Brandeis R, Raveh L, Grunwald J, Cohen E and Ashani Y (1993). Prevention of soman-induced cognitive deficits by pretreatment with human butyrylcholinesterase in rats. Pharmacol Biochem Behav 46: 889–896.
- Brimijoin S, Gao Y, Anker JJ, Gliddon LA, Lafleur D, Shah R, Zhao Q, Singh M and Carroll ME (2008). A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology 33: 2715–2725.
- Broomfield CA, Maxwell DM, Solana RP, Castro CA, Finger AV and Lenz DE (1991). Protection by Camp S, De Jaco A, Zhang L, Marquez M, De la Torre B and Taylor P (2008). Acetylcholinesterase expression in muscle is specifically controlled by a promoter-selective enhancesome in the first intron. J Neurosci 28: 2459–2470.
- Carletti E, Li H, Li B, Ekstrom F, Nicolet Y, Loiodice M, Gillon E, Froment MT, Lockridge O, Schopfer LM, Masson P and Nachon F (2008). Aging of cholinesterases phosphylated by tabun proceeds through o-dealkylation. J Am Chem Soc. 130: 16011–16020.
- Chatonnet F, Boudinot E, Chatonnet A, Taysse L, Daulon S, Champagnat J and Foutz AS (2003). Respiratory survival mechanisms in acetylcholinesterase knockout mouse. Eur J Neurosci 18: 1419–1427.
- Chitlaru T, Kronman C, Velan B and Shafferman A (2001). Effect of human acetylcholinesterase subunit assembly on its circulatory residence. Biochem J 354: 613–625.
- Darvesh S, McDonald RS, Darvesh KV, Mataija D, Mothana S, Cook H, Carneiro KM, Richard N, Walsh R and Martin E (2006). On the active site for hydrolysis of aryl amides and choline esters by human cholinesterases. Bioorg Med Chem 14: 4586–4599.
- De Vriese C, Gregoire F, Lema-Kisoka R, Waelbroeck M, Robberecht P and Delporte C (2004). Ghrelin degradation by serum and tissue homogenates: identification of the cleavage sites. Endocrinology 145: 4997–5005.
- Doctor BP and Saxena A (2005). Bioscavengers for the protection of humans against organophosphate toxicity. Chem Biol Interact 157–158: 167–171.
- Doctor BP, Raveh L, Wolfe AD, Maxwell DM and Ashani Y (1991). Enzymes as pretreatment drugs for organophosphate toxicity. Neurosci Biobehav Rev 15: 123–128.
- Duysen EG, Li B, Xie W, Schopfer LM, Anderson RS, Broomfield CA and Lockridge O (2001). Evidence for nonacetylcholinesterase targets of organophosphorus nerve agent: supersensitivity of acetylcholinesterase knockout mouse to VX lethality. J Pharmacol Exp Ther 299: 528–535.
- Duysen EG, Bartels CF and Lockridge O (2002a). Wild-type and A328W mutant human butyrylcholinesterase tetramers expressed in Chinese hamster ovary cells have a 16-hour half-life in the circulation and protect mice from cocaine toxicity. J Pharmacol Exp Ther 302: 751–758.
- Duysen EG, Stribley JA, Fry DL, Hinrichs SH and Lockridge O (2002b). Rescue of the acetylcholinesterase knockout mouse by feeding a liquid diet; phenotype of the adult acetylcholinesterase deficient mouse. Brain Res Dev Brain Res 137: 43–54.
- Duysen EG, Li B, Darvesh S and Lockridge O (2007). Sensitivity of butyrylcholinesterase knockout mice to (2)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission. Toxicology 233: 60–69.
- Duysen EG, Li B, Carlson M, Li Y, Wieseler S, Hinrichs SH and Lockridge O (2008). Increased hepatotoxicity and cardiac fibrosis in cocaine-treated butyrylcholinesterase knockout mice. Basic Clin Pharmacol Toxicol 103: 514–521.
- Evans FT, Gray PW, Lehmann H and Silk E (1953). Effect of pseudo-cholinesterase level on action of succinylcholine in man. Br Med J 1: 136–138.
- Feng G, Krejci E, Molgo J, Cunningham JM, Massoulie J and Sanes JR (1999). Genetic analysis of collagen Q: roles in acetylcholinesterase and butyrylcholinesterase assembly and in synaptic structure and function. J Cell Biol 144: 1349–1360.
- Gao Y and Brimijoin S (2004). An engineered cocaine hydrolase blunts and reverses cardiovascular responses to cocaine in rats. J Pharmacol Exp Ther 310: 1046–1052.
- Gatke MR, Ostergaard D, Bundgaard JR, Varin F and VibyMogensen J (2001). Response to mivacurium in a patient compound heterozygous for a novel and a known silent mutation in the butyrylcholinesterase gene: genotyping by sequencing. Anesthesiology 95: 600–606.
- Genovese RF and Doctor BP (1995). Behavioral and pharmacological assessment of butyrylcholinesterase in rats. Pharmacol Biochem Behav 51: 647–654.
- Getman DK, Eubanks JH, Camp S, Evans GA and Taylor P (1992). The human gene encoding acetylcholinesterase is located on the long arm of chromosome 7. Am J Hum Genet 51: 170–177.
- Girard E, Barbier J, Chatonnet A, Krejci E and Molgo J (2005). Synaptic remodeling at the skeletal neuromuscular junction of acetylcholinesterase knockout mice and its physiological relevance. Chem Biol Interact 157–158: 87–96.
- Goedde HW and Altland K (1971). Suxamethonium sensitivity. Ann NY Acad Sci 179: 695–703.
- Grunwald J, Marcus D, Papier Y, Raveh L, Pittel Z and Ashani Y (1997). Large-scale purification and long-term stability of human butyrylcholinesterase: a potential bioscavenger drug. J Biochem Biophys Methods 34: 123–135.
- Hartmann J, Kiewert C, Duysen EG, Lockridge O, Greig NH and Klein J (2007). Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity. J Neurochem 100: 1421–1429.
- Haupt H, Heide K, Zwisler O and Schwick HG (1966). [Isolation and physico-chemical characterization of cholinesterase in human serum]. Blut 14: 65–75.
- Hodgkin W, Giblett ER, Levine H, Bauer W and Motulsky AG (1965). Complete pseudocholinesterase deficiency: genetic and immunologic characterization. J Clin Invest 44: 486–493.
- Hoffman RS, Henry GC, Howland MA, Weisman RS, Weil L and Goldfrank LR (1992). Association between life-threatening cocaine toxicity and plasma cholinesterase activity. Ann Emerg Med 21: 247–253.
- Huang YJ, Huang Y, Baldassarre H, Wang B, Lazaris A, Leduc M, Bilodeau AS, Bellemare A, Cote M, Herskovits P, Touati M, Turcotte C, Valeanu L, Lemee N, Wilgus H, Begin I, Bhatia B, Rao K, Neveu N, Brochu E, Pierson J, Hockley DK, Cerasoli DM, Lenz DE, Karatzas CN and Langermann S (2007). Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. Proc Natl Acad Sci USA 104: 13603–13608.
- Huang YJ, Lundy PM, Lazaris A, Huang Y, Baldassarre H, Wang B, Turcotte C, Cote M, Bellemare A, Bilodeau AS, Brouillard S, Touati M, Herskovits P, Begin I, Neveu N, Brochu E, Pierson J, Hockley DK, Cerasoli DM, Lenz DE, Wilgus H, Karatzas CN and Langermann S (2008). Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin. BMC Biotechnol 8: 50.
- Jbilo O, Bartels CF, Chatonnet A, Toutant JP and Lockridge O (1994). Tissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA. Toxicon 32: 1445–1457.
- Jenkins T, Balinsky D and Patient DW (1967). Cholinesterase in plasma: first reported absence in the Bantu; half-life determination. Science 156: 1748–1750.
- Kalow W (2004). Atypical plasma cholinesterase. A personal discovery story: a tale of three cities. Can J Anaesth 51: 206–211.
- Kalow W and Staron N (1957). On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers. Can J Med Sci 35: 1305–1320.
- Klose R and Gutensohn G (1976). [Treatment of alkyl phosphate poisoning with purified serum cholinesterase (author's transl)]. Prakt Anaesth 11: 1–7.
- Kluge WH, Kluge HH, Hochstetter A, Vollandt R, Bauer HI and Venbrocks R (2001). Butyrylcholinesterase in lumbar and ventricular cerebrospinal fluid. Acta Neurol Scand 104: 17–23.
- Kolarich D, Weber A, Pabst M, Stadlmann J, Teschner W, Ehrlich H, Schwarz HP and Altmann F (2008). Glycoproteomic characterization of butyrylcholinesterase from human plasma. Proteomics 8: 254–263.
- Krejci E, Thomine S, Boschetti N, Legay C, Sketelj J and Massoulie J (1997). The mammalian gene of acetylcholinesterase-associated collagen. J Biol Chem 272: 22840–22847.
- Kutty KM, Huang SN and Kean KT (1981). Pseudocholinesterase in obesity: hypercaloric diet induced changes in experimental obese mice. Experientia 37: 1141–1142.
- Lenz DE, Maxwell DM, Koplovitz I, Clark CR, Capacio BR, Cerasoli DM, Federko JM, Luo C, Saxena A, Doctor BP and Olson C (2005). Protection against soman or VX poisoning by human butyrylcholinesterase in guinea pigs and cynomolgus monkeys. Chem Biol Interact 157–158: 205–210.
- Lenz DE, Yeung D, Smith JR, Sweeney RE, Lumley LA and Cerasoli DM (2007). Stoichiometric and catalytic scavengers as protection against nerve agent toxicity: a mini review. Toxicology 233: 31–39.
- Li B, Stribley JA, Ticu A, Xie W, Schopfer LM, Hammond P, Brimijoin S, Hinrichs SH and Lockridge O (2000). Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse. J Neurochem 75: 1320–1331.
- Li B, Duysen EG, Volpicelli-Daley LA, Levey AI and Lockridge O (2003). Regulation of muscarinic acetylcholine receptor function in acetylcholinesterase knockout mice. Pharmacol Biochem Behav 74: 977–986.
- Li B, Duysen EG, Carlson M and Lockridge O (2008a). The butyrylcholinesterase knockout mouse as a model for human butyrylcholinesterase deficiency. J Pharmacol Exp Ther 324: 1146–1154.
- Li B, Duysen EG and Lockridge O (2008b). The butyrylcholinesterase knockout mouse is obese on a high-fat diet. Chem Biol Interact 175: 88–91.
- Li H, Schopfer LM, Masson P and Lockridge O (2008c). Lamellipodin proline rich peptides associated with native plasma butyrylcholinesterase tetramers. Biochem J 411: 425–432.
- Liddell J, Lehmann H and Silk E (1962). A “silent” pseudo-cholinesterase gene. Nature 193: 561–562.
- Little JT, Walsh S and Aisen PS (2008). An update on huperzine A as a treatment for Alzheimer's disease. Expert Opin Investig Drugs 17: 209–215.
- Lockridge O (1988). Structure of human serum cholinesterase. Bioessays 9: 125–128.
- Lockridge O (1990). Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine. Pharmacol Ther 47: 35–60.
- Lockridge O and La Du BN (1982). Loss of the interchain disulfide peptide and dissociation of the tetramer following limited proteolysis of native human serum cholinesterase. J Biol Chem 257: 12012–12018.
- Lockridge O, Adkins S and La Du BN. (1987a). Location of disulfide bonds within the sequence of human serum cholinesterase. J Biol Chem 262: 12945–12952.
- Lockridge O, Bartels CF, Vaughan TA, Wong CK, Norton SE and Johnson LL (1987b). Complete amino acid sequence of human serum cholinesterase. J Biol Chem 262: 549–557.
- Lockridge O, Blong RM, Masson P, Froment MT, Millard CB and Broomfield CA (1997). A single amino acid substitution, Gly117 His, confers phosphotriesterase (organophosphorus acid anhydride hydrolase) activity on human butyrylcholinesterase. Biochemistry 36: 786–795.
- Lockridge O, Schopfer LM, Winger G and Woods JH (2005). Large scale purification of butyrylcholinesterase from human plasma suitable for injection into monkeys: a potential new therapeutic for protection against cocaine and nerve agent toxicity. J Med CBR Def 3 [online publication].
- Lynch TJ, Mattes CE, Singh A, Bradley RM, Brady RO and Dretchen KL (1997). Cocaine detoxification by human plasma butyrylcholinesterase. Toxicol Appl Pharmacol 145: 363–371.
- Manoharan I, Wieseler S, Layer PG, Lockridge O and Boopathy R (2006). Naturally occurring mutation Leu307Pro of human butyrylcholinesterase in the Vysya community of India. Pharmacogenet Genomics 16: 461–468.
- Manoharan I, Boopathy R, Darvesh S and Lockridge O (2007). A medical health report on individuals with silent butyrylcholinesterase in the Vysya community of India. Clin Chim Acta 378: 128–135.
- Masson P, Froment MT, Bartels CF and Lockridge O (1996). Asp7O in the peripheral anionic site of human butyrylcholinesterase. Eur J Biochem 235: 36–48.
- Masson P, Legrand P, Bartels CF, Froment MT, Schopfer LM and Lockridge O (1997). Role of aspartate 70 and tryptophan 82 in binding of succinyldithiocholine to human butyrylcholinesterase. Biochemistry 36: 2266–2277.
- Masson P, Froment MT, Gillon E, Nachon F, Darvesh S and Schopfer LM (2007). Kinetic analysis of butyrylcholinesterasecatalyzed hydrolysis of acetanilides. Biochim Biophys Acta 1774: 1139–1147.
- Masson P, Froment MT, Gillon E, Nachon F, Lockridge O and Schopfer LM (2008). Kinetic analysis of effector modulation of butyrylcholinesterase-catalysed hydrolysis of acetanilides and homologous esters. Febs J 275: 2617–2631.
- Matzke SM, Oubre JL, Caranto GR, Gentry MK and Galbicka G (1999). Behavioral and immunological effects of exogenous butyrylcholinesterase in rhesus monkeys. Pharmacol Biochem Behav 62: 523–530.
- Maxwell DM, Castro CA, De La Hoz DM, Gentry MK, Gold MB, Solana RP, Wolfe AD and Doctor BP (1992). Protection of rhesus monkeys against soman and prevention of performance decrement by pretreatment with acetylcholinesterase. Toxicol Appl Pharmacol 115: 44–49.
- Maxwell DM, Brecht KM, Doctor BP and Wolfe AD (1993). Comparison of antidote protection against soman by pyridostig-mine, HI-6 and acetylcholinesterase. J Pharmacol Exp Ther 264: 1085–1089.
- McArdle JJ, Sellin LC, Coakley KM, Potian JG, Quinones-Lopez MC, Rosenfeld CA, Sultatos LG and Hognason K (2005). Mefloquine inhibits cholinesterases at the mouse neuromuscular junction. Neuropharmacology 49: 1132–1139.
- McDonough JH, Jr. and Shih TM (1997). Neuropharmacological mechanisms of nerve agent-induced seizure and neuropathology. Neurosci Biobehav Rev 21: 559–579.
- McGuire MC, Nogueira CP, Bartels CF, Lightstone H, Hajra A, Van der Spek AF, Lockridge O and La Du BN (1989). Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc Natl Acad Sci USA 86: 953–957.
- Mesulam MM and Geula C (1994). Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 36: 722–727.
- Mesulam MM, Guillozet A, Shaw P, Levey A, Duysen EG and Lockridge O (2002). Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 110: 627–639.
- Millard CB, Lockridge O and Broomfield CA (1995). Design and expression of organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase. Biochemistry 34: 15925–15933.
- Millard CB, Lockridge O and Broomfield CA (1998). Organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase: synergy results in a somanase. Biochemistry 37: 237–247.
- Minic J, Chatonnet A, Krejci E and Molgo J (2003). Butyrylcholinesterase and acetylcholinesterase activity and quantal transmitter release at normal and acetylcholinesterase knockout mouse neuromuscular junctions. Br J Pharmacol 138: 177–187.
- Myslivecek J, Duysen EG and Lockridge O (2007). Adaptation to excess acetylcholine by downregulation of adrenoceptors and muscarinic receptors in lungs of acetylcholinesterase knockout mice. Naunyn Schmiedebergs Arch Pharmacol 376: 83–92.
- Nachon F, Ehret-Sabatier L, Loew D, Colas C, van Dorsselaer A and Goeldner M (1998). Trp82 and Tyr332 are involved in two quaternary ammonium binding domains of human butyrylcholinesterase as revealed by photoaffinity labeling with [3H]DDF. Biochemistry 37: 10507–10513.
- Nachon F, Masson P, Nicolet Y, Lockridge O and Fontecilla-Camps JC (2003). Comparison of the structures of butyrylcholinesterase and acetylcholinesterase. Martin Dunitz, London.
- Nachon F, Asojo OA, Borgstahl GE, Masson P and Lockridge O (2005). Role of water in aging of human butyrylcholinesterase inhibited by echothiophate: the crystal structure suggests two alternative mechanisms of aging. Biochemistry 44: 1154–1162.
- Naguib M, Daoud W, el-Gammal M, Ammar A, Turkistani A, Selim M, Altamimi W and Sohaibani MO (1995a). Enzymatic antagonism of mivacurium-induced neuromuscular blockade by human plasma cholinesterase. Anesthesiology 83: 694–701.
- Naguib M, el-Gammal M, Daoud W, Ammar A, Moukhtar H and Turkistani A (1995b). Human plasma cholinesterase for antagonism of prolonged mivacurium-induced neuromuscular blockade. Anesthesiology 82: 1288–1292.
- Naguib M, Samarkandi AH, Bakhamees HS, Turkistani A and Alharby SW (1996a). Edrophonium and human plasma cholinesterase combination for antagonism of mivacurium-induced neuromuscular block. Br J Anaesth 77: 424–426.
- Naguib M, Selim M, Bakhamees HS, Samarkandi AH and Turkistani A (1996b). Enzymatic versus pharmacologic antagonism of profound mivacurium- induced neuromuscular blockade. Anesthesiology 84: 1051–1059.
- Ndikum-Moffor FM and Roberts SM (2003). Cocaine-protein targets in mouse liver. Biochem Pharmacol 66: 105–113.
- Ndikum-Moffor FM, Schoeb TR and Roberts SM (1998). Liver toxicity from norcocaine nitroxide, an N-oxidative metabolite of cocaine. J Pharmacol Exp Ther 284: 413–419.
- Nicolet Y, Lockridge O, Masson P, Fontecilla-Camps JC and Nachon F (2003). Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem 278: 41141–41147.
- Noureddine H, Carvalho S, Schmitt C, Massoulie J and Bon S (2008). Acetylcholinesterase associates differently with its anchoring proteins ColQ and PRiMA. J Biol Chem 283: 20722–20732.
- Ohbu S, Yamashina A, Takasu N, Yamaguchi T, Murai T, Nakano K, Matsui Y, Mikami R, Sakurai K and Hinohara S (1997). Sarin poisoning on Tokyo subway. South Med J 90: 587–593.
- Ostergaard D, Viby-Mogensen J, Hanel HK and Skovgaard LT (1988). Half-life of plasma cholinesterase. Acta Anaesthesiol Scand 32: 266–269.
- Ostergaard D, Jensen FS and Viby-Mogensen J (1995). Reversal of intense mivacurium block with human plasma cholinesterase in patients with atypical plasma cholinesterase. Anesthesiology 82: 1295–1298.
- Ostergaard D, Viby-Mogensen J, Rasmussen SN, Gatke MR and Varin F (2005). Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically homozygous for the atypical plasma cholinesterase variant: effect of injection of human cholinesterase. Anesthesiology 102: 1124–1132.
- Pedron N (1983). Cholinesterase activity of seminal plasma and human spermatozoa in normal and infertile subjects. Arch Androl 10: 249–251.
- Perrier AL, Massoulie J and Krejci E (2002). PRiMA: the membrane anchor of acetylcholinesterase in the brain. Neuron 33: 275–285.
- Ploier R. (1975). [A kin with a “silent” pseudocholinesterase gene (author's transl)]. Z Kinderheilkd 119: 31–36.
- Poyot T, Nachon F, Froment MT, Loiodice M, Wieseler S, Schopfer LM, Lockridge O and Masson P (2006). Mutant of Bungarus fasciatus acetylcholinesterase with low affinity and low hydrolase activity toward organophosphorus esters. Biochim Biophys Acta 1764: 1470–1478.
- Raveh L, Ashani Y, Levy D, De La Hoz D, Wolfe AD and Doctor BP (1989). Acetylcholinesterase prophylaxis against organophosphate poisoning. Quantitative correlation between protection and blood-enzyme level in mice. Biochem Pharmacol 38: 529–534.
- Raveh L, Grunwald J, Marcus D, Papier Y, Cohen E and Ashani Y (1993). Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. In vitro and in vivo quantitative characterization. Biochem Pharmacol 45: 2465–2474.
- Raveh L, Grauer E, Grunwald J, Cohen E and Ashani Y (1997). The stoichiometry of protection against soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase. Toxicol Appl Pharmacol 145: 43–53.
- Razon N, Soreq H, Roth E, Bartal A and Silman I (1984). Characterization of activities and forms of cholinesterases in human primary brain tumors. Exp Neurol 84: 681–695.
- Roberts WL, Santikarn S, Reinhold VN and Rosenberry TL (1988). Structural characterization of the glycoinositol phospholipid membrane anchor of human erythrocyte acetylcholinesterase by fast atom bombardment mass spectrometry. J Biol Chem 263: 18776–18784.
- Rosenberg Y, Luo C, Ashani Y, Doctor BP, Fischer R, Wolfe G and Saxena A (2002). Pharmacokinetics and immunologic consequences of exposing macaques to purified homologous butyrylcholinesterase. Life Sci 72: 125–134.
- Rosenberry TL and Scoggin DM (1984). Structure of human erythrocyte acetylcholinesterase. Characterization of intersubunit disulfide bonding and detergent interaction. J Biol Chem 259: 5643–5652.
- Rosenberry TL, Chen JF, Lee MM, Moulton TA and Onigman P (1981). Large scale isolation of human erythrocyte membranes by high volume molecular filtration. J Biochem Biophys Methods 4: 39–48.
- Ryhanen RJ (1983). Pseudocholinesterase activity in some human body fluids. Gen Pharmacol 14: 459–460.
- Saxena A, Ashani Y, Raveh L, Stevenson D, Patel T and Doctor BP (1998). Role of oligosaccharides in the pharmacokinetics of tissue-derived and genetically engineered cholinesterases. Mol Pharmacol 53: 112–122.
- Saxena A, Sun W, Luo C, Myers TM, Koplovitz I, Lenz DE and Doctor BP (2006). Bioscavenger for protection from toxicity of organophosphorus compounds. J Mol Neurosci 30: 145–148.
- Schallreuter KU, Gibbons NC, Elwary SM, Parkin SM and Wood JM (2007). Calcium-activated butyrylcholinesterase in human skin protects acetylcholinesterase against suicide inhibition by neurotoxic organophosphates. Biochem Biophys Res Commun 355: 1069–1074.
- Scholler KL, Goedde HW and Benkmann HG (1977). The use of serum cholinesterase in succinylcholine apnoea. Can Anaesth Soc J 24: 396–400.
- Schuh FT (1977). Serum cholinesterase: effect on the action of suxamethonium following administration to a patient with cholinesterase deficiency. Br J Anaesth 49: 269–272.
- Souza RL, Mikami LR, Maegawa RO and Chautard-Freire-Maia EA (2005). Four new mutations in the BCHE gene of human butyrylcholinesterase in a Brazilian blood donor sample. Mol Genet Metab 84: 349–353.
- Stewart DJ, Inaba T, Tang BK and Kalow W (1977). Hydrolysis of cocaine in human plasma by cholinesterase. Life Sci 20: 1557–1563.
- Stovner J and Stadskleiv K (1976). Suxamethonium apnoea terminated with commercial serum cholinesterase. Acta Anaesthesiol Scand 20: 211–215.
- Sun H, Shen ML, Pang YP, Lockridge O and Brimijoin S (2002). Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase. J Pharmacol Exp Ther 302: 710–716.
- Tschop M, Smiley DL and Heiman ML (2000). Ghrelin induces adiposity in rodents. Nature 407: 908–913.
- Ueno H, Yamaguchi H, Kangawa K and Nakazato M (2005). Ghrelin: a gastric peptide that regulates food intake and energy homeostasis. Regul Pept 126: 11–19.
- Velan B, Kronman C, Ordentlich A, Flashner Y, Leitner M, Cohen S and Shafferman A (1993). N-glycosylation of human acetylcholinesterase: effects on activity, stability and biosynthesis. Biochem J 296 (Pt 3): 649–656.
- Viby-Mogensen J (1981). Succinylcholine neuromuscular blockade in subjects homozygous for atypical plasma cholinesterase. Anesthesiology 55: 429–434.
- Vignaud A, Fougerousse F, Mouisel E, Guerchet N, Hourde C, Bacou F, Butler-Browne GS, Chatonnet A and Ferry A (2008). Genetic inactivation of acetylcholinesterase causes functional and structural impairment of mouse soleus muscles. Cell Tissue Res 333: 289–296.
- Volpicelli-Daley LA, Duysen EG, Lockridge O and Levey AI (2003). Altered hippocampal muscarinic receptors in acetylcholinesterase-deficient mice. Ann Neurol 53: 788–796.
- Wang Y, Boeck AT, Duysen EG, Van Keuren M, Saunders TL and Lockridge O (2004). Resistance to organophosphorus agent toxicity in transgenic mice expressing the G117H mutant of human butyrylcholinesterase. Toxicol Appl Pharmacol 196: 356–366.
- Whittaker M (1980). Plasma cholinesterase variants and the anaesthetist. Anaesthesia 35: 174–197.
- Wolfe AD, Blick DW, Murphy MR, Miller SA, Gentry MK, Hartgraves SL and Doctor BP (1992). Use of cholinesterases as pretreatment drugs for the protection of rhesus monkeys against soman toxicity. Toxicol Appl Pharmacol 117: 189–193.
- Xie W, Altamirano CV, Bartels CF, Speirs RJ, Cashman JR and Lockridge O (1999). An improved cocaine hydrolase: the A328Y mutant of human butyrylcholinesterase is 4-fold more efficient. Mol Pharmacol 55: 83–91.
- Xie W, Stribley JA, Chatonnet A, Wilder PJ, Rizzino A, McComb RD, Taylor P, Hinrichs SH and Lockridge O (2000). Postnatal developmental delay and supersensitivity to organo-phosphate in gene-targeted mice lacking acetylcholinesterase. J Pharmacol Exp Ther 293: 896–902.
- Yeary RA, Eaton J, Gilmore E, North B and Singell J (1993). A multiyear study of blood cholinesterase activity in urban pesticide applicators. J Toxicol Environ Health 39: 11–25.
- Zheng F, Yang W, Ko MC, Liu J, Cho H, Gao D, Tong M, Tai HH, Woods JH and Zhan CG (2008). Most efficient cocaine hydro-lase designed by virtual screening of transition states. J Am Chem Soc 130: 12148–12155.
